ACADIA Pharmaceuticals(ACAD) - 2024 Q3 - Quarterly Report

Product Portfolio - NUPLAZID and DAYBUE are the company's commercial portfolio products, with NUPLAZID approved in April 2016 and DAYBUE in March 2023[86][99]. - The FDA approved DAYBUE for the treatment of Rett syndrome, making it the first and only drug approved for this condition in the U.S.[86]. - DAYBUE received marketing authorization in Canada for the treatment of Rett syndrome in October 2024, marking it as the first approved drug for this condition in Canada[93]. Research and Development - The company has incurred significant research and development expenses, with a focus on products like pimavanserin, trofinetide, ACP-101, and ACP-204[102]. - The company initiated a Phase 3 study for ACP-101 in November 2023, targeting hyperphagia in Prader-Willi syndrome[94]. - Research and development expenses decreased to $66.6 million for the three months ended September 30, 2024, from$157.0 million for the same period in 2023[114]. - Research and development expenses for the nine months ended September 30, 2024, totaled $202.5 million, down from$284.9 million in 2023[122]. Financial Performance - As of September 30, 2024, the company reported an accumulated deficit of $2.3 billion, indicating substantial operating losses primarily due to research and development expenditures[97]. - Net product sales for the three months ended September 30, 2024, were$250.4 million, an increase from $211.7 million in 2023[111]. - Net product sales of NUPLAZID increased to$159.2 million for the three months ended September 30, 2024, compared to $144.8 million in 2023, reflecting a growth of$14.4 million[112]. - Net product sales of DAYBUE rose to $91.2 million for the three months ended September 30, 2024, up from$66.9 million in 2023, an increase of $24.3 million[112]. - Net product sales for the nine months ended September 30, 2024, were$698.2 million, compared to $495.4 million in 2023[116]. - Net product sales of NUPLAZID for the nine months ended September 30, 2024, were$446.5 million, an increase of $41.2 million from$405.3 million in 2023[117]. - Net product sales of DAYBUE surged to $251.7 million for the nine months ended September 30, 2024, compared to$90.1 million in 2023, an increase of $161.6 million[117]. Expenses - Selling, general and administrative expenses increased to$133.3 million for the three months ended September 30, 2024, from $97.9 million in 2023[115]. - Selling, general and administrative expenses increased to$358.3 million for the nine months ended September 30, 2024, from $295.1 million for the same period in 2023, representing a 21.4$60.0 million, representing approximately 9% of net product sales, compared to $23.7 million or 5$117.3 million for the nine months ended September 30, 2024, compared to a net cash used of $68.7 million for the same period in 2023[132]. - Cash, cash equivalents, and investment securities totaled$565.3 million at September 30, 2024, up from $438.9 million at December 31, 2023, marking a$126.4 million increase[132]. - Net cash used in investing activities totaled $152.7 million for the nine months ended September 30, 2024, compared to$32.3 million of net cash provided in the same period in 2023[133]. - Net cash provided by financing activities decreased to $4.9 million for the nine months ended September 30, 2024, down from$19.7 million for the same period in 2023[134]. - The company expects cash, cash equivalents, and securities to be sufficient to fund planned operations through and beyond the next 12 months[124]. - The company may require additional financing in the future to fund operations, depending on various factors including the costs of acquiring additional product candidates[124]. - The company is required to make milestone payments of $50.0 million within 60 days following Neuren's invoice delivery after December 31, 2024, due to exceeding$250.0 million in net revenue from trofinetide in North America[130]. Licensing and Market Expansion - The company expanded its licensing agreement with Neuren in July 2023, acquiring global rights for trofinetide and NNZ-2591, with potential milestone payments totaling up to $1.257 billion[92]. - The company is exploring additional markets for trofinetide, with plans for a filing in Europe anticipated in Q1 2025[93]. - The company has fulfilled one of the five post-marketing requirements for DAYBUE and is awaiting FDA's acknowledgment for another completed requirement[102]. Investment Portfolio - The investment portfolio has not been adversely impacted by past disruptions in credit markets, but future disruptions could affect it[127].